TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19959493
Drug: Treatment modalities
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment modalities (both enoxaparin and UFH)
Study: 17669110
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg once daily (ALL-500 group)
Study: 17669110
Drug: Levofloxacin 1000
Normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 1000 mg twice daily (ALL-1000 group)
Study: 17669110
Drug: Post-treatment value
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment value of (13)C-urea breath test <= 15 in ALL-500 group
Study: 17669110
Drug: Post-treatment value
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment value of (13)C-urea breath test > 15 in ALL-500 group
Study: 17669110
Drug: Post-treatment value
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment value of (13)C-urea breath test <= 15 in ALL-1000 group
Study: 17669110
Drug: Post-treatment value
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment value of (13)C-urea breath test > 15 in ALL-1000 group
Study: 16478369
Drug: Concurrent feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent feedback group (real-time EMG waveform displays)
Study: 7534450
Drug: Hebrew version
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hebrew version of the MAP administered to Israeli children
Study: 20727
Drug: Diazepam (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.2 to 0.6 mg/kg)
Study: 20727
Drug: Flunitrazepam (equipotent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (equipotent doses)
Study: 21297074
Drug: Tifacogin 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tifacogin 0.025 mg/kg/h
Study: 10769331
Drug: Bran treatment
Normalized name: bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bran treatment (gradually increasing daily doses of a bran mixture)
Study: 9152656
Drug: Frusemide 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 40 mg o.d.
Study: 9152656
Drug: Ibopamine 100
Normalized name: ibopamine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine 100 mg t.d.s.
Study: 3739583
Drug: Intravenous methohexitone
Normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methohexitone
Study: 30802723
Drug: Fuji apple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuji apple intake (2 apples, 360 g per day for 1 week)
Study: 17227902
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) 50 mg/m2 every 28 days
Study: 27798749
Drug: Capecitabine 1250
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1250 mg/m2 twice daily for 14 days every 21 days
Study: 25138661
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g dose of the whole-grain fibre composite ingredient
Study: 25138661
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g dose of the whole-grain fibre composite ingredient
Study: 25138661
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of the whole-grain fibre composite ingredient
Study: 22771160
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine (oral care with a toothbrush and antiseptic gel twice a day)
Study: 22771160
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral care with a toothbrush and non-antiseptic gel twice a day)
Study: 17599102
Drug: Zinacef (Cefuroxime)
Normalized name: cefuroxime Injection [Zinacef]
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinacef (Cefuroxime) 1.5 g intravenously at induction and 750 mg six hourly for 12 hours (Group 2)
Study: 17599102
Drug: Ciprotab (ciprofloxacine)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprotab (ciprofloxacine) 400mg intravenously at induction and 200mg six hourly for 12 hours (Group 3)
Study: 17599102
Drug: Cost-effectiveness comparison
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost-effectiveness comparison of the three antibiotics
Study: 10220207
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro injected at 0 min before a standard lunch with a mid-afternoon snack
Study: 7882475
Drug: Angiopeptin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiopeptin (3 mg per 24 hours before PTCA followed by 6 mg per 24 hours after PTCA)
Study: 2122016
Drug: Intravenous L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-carnitine (50 mumol/kg/day for 7 days, then 100 mumol/kg/day for 7 days)
Study: 26265063
Drug: Amoxicillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (1 g) 1 h before surgery + 500 mg 8/8 h for 7 days
Study: 26265063
Drug: Amoxicillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (1 g) 1 h before surgery + placebo (identical appearance to G1) 8/8 h for 7 days
Study: 26265063
Drug: Placebo 1
Normalized name: placebo 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 h before surgery and 500 mg 8/8 h for 7 days
Study: 17302696
Drug: Intracoronary enalaprilat
Normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary enalaprilat (EN), 50 mug, administered immediately after reperfusion
Study: 17302696
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) administered immediately after reperfusion
Study: 9330414
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 50 micrograms twice daily (b.i.d.)
Study: 9330414
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG) 20 mg four times daily (q.i.d.)
Study: 7953445
Drug: Anterograde delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterograde delivered cardioplegic solution (Group A, n = 19)
Study: 7953445
Drug: Retrograde delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrograde delivered cardioplegic solution (Group B, n = 17)
Study: 6385797
Drug: Continued chemotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued chemotherapy (n=46)
Study: 31246894
Drug: Indapamide 1.5
Normalized name: indapamide 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 1.5 mg sustained release/Amlodipine 5 mg SPC
Study: 31246894
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg/Valsartan 80 mg SPC
Study: 16409523
Drug: Using the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using the drug on prescription (PD)
Study: 15245937
Drug: Sacral nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacral nerve stimulation therapy
Study: 15245937
Drug: Delayed implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implant group (Control)
Study: 6472116
Drug: Diet A
Normalized name: Diet Aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet A (360 kcal, 1.5 g egg protein per kg IBW, no carbohydrate)
Study: 6472116
Drug: Diet B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet B (340 kcal, 0.8 g egg protein per kg IBW, 0.7 g carbohydrate per kg IBW)
Study: 31912474
Drug: diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac sodium 50 mg bid
Study: 31912474
Drug: tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamsulosin 0.2 mg sid
Study: 31912474
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of tamsulosin and diclofenac sodium
Study: 30277539
Drug: Genetically predicted
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically predicted fasting insulin
Study: 28433432
Drug: Low-Dose-Rate Prostate
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Dose-Rate Prostate Brachytherapy (LDR-PB) boost
Study: 28433432
Drug: Dose-Escalated External
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-Escalated External Beam Radiation Therapy (DE-EBRT) boost
Study: 23611930
Drug: Nitrofurantoin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin (100 mg 2 times a day for 3 days)
Study: 20724299
Drug: Standard surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard surgical treatment; n = 90
Study: 19785725
Drug: Intracoronary abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary abciximab administration
Study: 19785725
Drug: Intravenous abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous abciximab administration
Study: 16400064
Drug: Mixed carotenoids
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed carotenoids (beta‐carotene, lutein, and lycopene; 4 mg each)
Study: 16400064
Drug: Beta‐carotene (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta‐carotene (12 mg)
Study: 14965157
Drug: Adverse drug
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse drug event tracking calendar provided to the intervention group
Study: 9018184
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone (2 mg/kg)
Study: 9018184
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (2 mg/kg)
Study: 9018184
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (oral and i.v.)
Study: 8475622
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of aspirin for asymptomatic patients
Study: 3530595
Drug: U-40 insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: U-40 insulin
Study: 3530595
Drug: U-100 insulin
Normalized name: SafeSnap 1mL U-100 Insulin Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: U-100 insulin
Study: 29773079
Drug: Linagliptin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin (5 mg once daily for 12 weeks)
Study: 20202800
Drug: Drug Attitude
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug Attitude Inventory (DAI) assessment
Study: 18375253
Drug: Rosiglitazone added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone added to metformin (RM)
Study: 16470423
Drug: Ibuprofen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1 week postoperatively)
Study: 16470423
Drug: Ibuprofen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (2 weeks postoperatively)
Study: 16470423
Drug: Ibuprofen (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (combined treatment)
Study: 12351281
Drug: gabapentin 1200
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gabapentin 1200 mg/d
Study: 30475165
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate (given for four days)
Study: 10983860
Drug: Pivampicillin 700
Normalized name: pivampicillin
DrugBank: Pivampicillin (DB01604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivampicillin 700 mg twice daily for 10 days
Study: 20498136
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of lorazepam
Study: 19112786
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of pre-oxygenated HBOC-201
Study: 19112786
Drug: Dry occlusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry occlusion (without HBOC-201 infusion)
Study: 16404407
Drug: sibutramine 10
Normalized name: sibutramine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: sibutramine 10 mg once daily plus behavioral therapy
Study: 16404407
Drug: behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: behavioral therapy alone (control)
Study: 10805062
Drug: Emedastine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emedastine (4 mg q.d.)
Study: 10805062
Drug: Emedastine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emedastine (2 mg b.i.d.)
Study: 10805062
Drug: Cetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (10 mg q.d.)
Study: 4028596
Drug: Tc‐99m pyrophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tc‐99m pyrophosphate (PYP) with 3.4 mg of stannous chloride
Study: 4028596
Drug: Tc‐99m methylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tc‐99m methylene diphosphonate (MDP) with 3.4 mg of stannous chloride
Study: 4028596
Drug: Tc‐99m methylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tc‐99m methylene diphosphonate (MDP) with 1.0 mg of stannous chloride
Study: 24611852
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care therapy (Controls)
Study: 14639675
Drug: Pramipexole (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (1.5 mg t.i.d.)
Study: 14639675
Drug: Pergolide (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide (1.5 mg t.i.d.)
Study: 8676625
Drug: Fludarabine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine (25 mg/m2 per day on days 1-5 for six courses)
Study: 8676625
Drug: CAP (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP (cyclophosphamide 750 mg/m2 per day and doxorubicin 50 mg/m2 per day on day 1, and prednisone 40 mg/m2 per day on days 1-5 for six courses)
Study: 6093845
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of ketoconazole
Study: 25289840
Drug: Low-load resistance
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-load resistance training with concurrent blood flow restriction (BFR)
Study: 22016276
Drug: Isotretinoin 1
Normalized name: isotretinoin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin 1 mg/kg/day (Group A)
Study: 22016276
Drug: Isotretinoin 1
Normalized name: isotretinoin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin 1 mg/kg alternate day (Group B)
Study: 22016276
Drug: Isotretinoin 1
Normalized name: isotretinoin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin 1 mg/kg/day for one week/four weeks (Group C)
Study: 22016276
Drug: Isotretinoin 20
Normalized name: isotretinoin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin 20 mg every alternate day for 16 weeks (Group D)
Study: 16883263
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading dose, followed by 75 mg/day after Day 2) in addition to conventional therapy (TLT, aspirin, statin, ACE inhibitor, beta-blocker)
Study: 16883263
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy only (TLT, aspirin, statin, ACE inhibitor, beta-blocker)
Study: 9928580
Drug: Alternating adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating adjuvant chemotherapy
Study: 8035946
Drug: Albendazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (15 mg/kg/d) for 1 week
Study: 30488800
Drug: Deprox 500®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deprox 500® (2 tablets/day for 6 weeks)
Study: 30488800
Drug: Serenoa repens
Normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serenoa repens (320 mg, 1 tablet/day for 6 weeks)
Study: 21921100
Drug: Strategy 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strategy 2 (referral if 2 out of 5 criteria are positive: inflammatory back pain, HLA‐B27, sacroiliitis detected by imaging, positive family history of ankylosing spondylitis, or good treatment response to NSAIDs)
Study: 19734968
Drug: Surgery (preferred
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery (preferred treatment)
Study: 19734968
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment modalities (not specified)
Study: 15315512
Drug: Pregabalin (effective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (effective dose range 150-600 mg/day)
Study: 15315512
Drug: Pregabalin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (two times daily vs three times daily)
Study: 11143188
Drug: 7-day intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day intravenous eflornithine (100 mg/kg every 6 h)
Study: 9269608
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine and bacterial immunostimulant
Study: 3690187
Drug: BCG Pasteur
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG Pasteur (L'Institut Pasteur, France)
Study: 22094636
Drug: TetraMen-T (alternative
Approvals — FDA: no, EMA: no, PMDA: no
Description: TetraMen-T (alternative formulations)
Study: 22094636
Drug: Neisvac-C (licensed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neisvac-C (licensed adjuvanted serogroup C conjugate vaccine)
Study: 20797475
Drug: Flaxseed lignan
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed lignan (SDG) 100 mg/d
Study: 20797475
Drug: Flaxseed lignan
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed lignan (SDG) 20 mg/d
Study: 12755526
Drug: Propofol target
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target controlled infusion at 4 mcg/mL
Study: 12755526
Drug: Propofol target
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target controlled infusion at 5 mcg/mL
Study: 12755526
Drug: Propofol target
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target controlled infusion at 6 mcg/mL
Study: 11184063
Drug: Dietary therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary therapy candidates according to NCEP II guidelines
Study: 11184063
Drug: Dietary therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary therapy candidates according to European guidelines
Study: 11184063
Drug: Antilipemic drug
Normalized name: ANTILIPEMIC AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antilipemic drug therapy candidates according to NCEP II guidelines
Study: 11184063
Drug: Antilipemic drug
Normalized name: ANTILIPEMIC AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antilipemic drug therapy candidates according to European guidelines
Study: 11184063
Drug: Dietary therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary therapy received by diagnosed dietary therapy candidates according to NCEP II guidelines
Study: 11184063
Drug: Dietary therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary therapy received by diagnosed dietary therapy candidates according to European guidelines
Study: 11184063
Drug: Antilipemic drug
Normalized name: ANTILIPEMIC AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antilipemic drug therapy received by diagnosed drug therapy candidates according to NCEP II guidelines
Study: 11184063
Drug: Antilipemic drug
Normalized name: ANTILIPEMIC AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antilipemic drug therapy received by diagnosed drug therapy candidates according to European guidelines
Study: 11184063
Drug: Diagnosis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnosis of high blood cholesterol levels among NCEP II drug therapy candidates
Study: 11184063
Drug: Diagnosis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnosis of high blood cholesterol levels among European drug therapy candidates
Study: 8270437
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy plus hyperthermia
Study: 31586600
Drug: SB206 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB206 4% twice daily
Study: 31586600
Drug: SB206 8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB206 8% twice daily
Study: 31586600
Drug: SB206 12%
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB206 12% twice daily
Study: 31586600
Drug: SB206 12%
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB206 12% once daily
Study: 31586600
Drug: SB206 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB206 (all doses)
Study: 31586600
Drug: SB206 4%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB206 4%, 8%, and 12% twice daily
Study: 30630791
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (exposed to clopidogrel and aspirin)
Study: 30630791
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not exposed to clopidogrel and aspirin)
Study: 26073395
Drug: 0 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g/d EPA + DHA (placebo)
Study: 26073395
Drug: 0.85 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.85 g/d EPA + DHA (low dose)
Study: 26073395
Drug: 3.4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.4 g/d EPA + DHA (high dose)